Compare Microsoft (MSFT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Repligen Corporation Common Stock — how do they compare? Microsoft trades at $531.94 (market cap $3.96T), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Microsoft is far larger — about 350.1× Repligen Corporation Common Stock's market cap, and Microsoft pays a 0.73% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Repligen Corporation Common Stock for 0 Days on average.
| MSFT | RGEN | |
|---|---|---|
Market Cap | $3.96T | $11.31B |
Volume | 22,251,503 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $543.45 | $194.57 |
52-Week Low | $352.83 | $102.87 |
Typical Hold Time | 142 Days | 0 Days |
Enterprise Value | $3.94T | $11.20B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $543.45, up 0.43% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.74 beating estimates of $4.24, continuing a trend of earnings outperformance. Revenue growth accelerated to $281.72B in 2025 with impressive 40.31% net income margin. Analyst consensus remains overwhelmingly positive with 82% buy ratings and $577.52 price target representing 6.3% upside potential.
Microsoft's AI leadership and cloud dominance position it for sustained growth, though elevated P/E of 30.28 and RSI levels near 83 suggest potential near-term consolidation. Key risks include increased capital expenditure pressures and competitive threats in AI infrastructure. The stock offers strong long-term prospects but may face volatility from valuation concerns and macroeconomic headwinds affecting tech sector performance.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
